Predict your next investment

HEALTHCARE | Drug Development
oncoimmune.com

See what CB Insights has to offer

Executives

4

Board of Directors

1

OncoImmune Board of Director

1 Board of directors

OncoImmune has 1 board of directors, including Karen Liu.

Name

Firm

Work History

Other Seats

Karen Liu

Dr. Karen Liu is a founding partner of 3E Bioventures Capital, a fund that focuses on venture investments in healthcare related sectors, such as drug, device, diagnostics, increasingly, interdisciplinary innovations at the frontier of BT (Biotech) and IT (information technology). While 3E primarily invests in China, it is also actively exploring cross-border investment opportunities with China angle or can leverage China advantages. Dr. Karen Liu has been active in China healthcare venture investment since 2006. Her past investments include device companies such as Reach Surgical, Sinomed, diagnostic companies such as Biochain, Micropoint, BGI, drug related companies such as Chiral Quest, Shenogen and mobile health company such as Apricot Forest. Prior to 3E Bioventures, Karen was a partner at Kaiwu Capital in charge of healthcare investment from 2011-2015 and before that, was Managing Director at CRCI Capital from 2007-2011, also in charge of healthcare investment. In 2006, Karen co-founded Shenogen Pharma, a company developing innovative liver cancer therapeutics, and was its first angle investor. From 2000-2004, she was an entrepreneur and senior team member of 3721, an Internet search company founded by Internet veteran Hongyi Zhou. She helped build up the small internet company and achieved profitability and eventually sold it to Yahoo in early 2004. Karen Liu also worked as a consultant at McKinsey & Company from 1998-2000. Dr. Liu received her Ph.D degree in Immunology from Harvard University and Master of Medical Sciences degree from Harvard Medical School. She also received her Bachelor of Sciences degree from Cornell University and her EMBA degree from CKGSB – Chungkong Graduate School of Business in China.

OncoImmune

Name

Karen Liu

Firm

Work History

Dr. Karen Liu is a founding partner of 3E Bioventures Capital, a fund that focuses on venture investments in healthcare related sectors, such as drug, device, diagnostics, increasingly, interdisciplinary innovations at the frontier of BT (Biotech) and IT (information technology). While 3E primarily invests in China, it is also actively exploring cross-border investment opportunities with China angle or can leverage China advantages. Dr. Karen Liu has been active in China healthcare venture investment since 2006. Her past investments include device companies such as Reach Surgical, Sinomed, diagnostic companies such as Biochain, Micropoint, BGI, drug related companies such as Chiral Quest, Shenogen and mobile health company such as Apricot Forest. Prior to 3E Bioventures, Karen was a partner at Kaiwu Capital in charge of healthcare investment from 2011-2015 and before that, was Managing Director at CRCI Capital from 2007-2011, also in charge of healthcare investment. In 2006, Karen co-founded Shenogen Pharma, a company developing innovative liver cancer therapeutics, and was its first angle investor. From 2000-2004, she was an entrepreneur and senior team member of 3721, an Internet search company founded by Internet veteran Hongyi Zhou. She helped build up the small internet company and achieved profitability and eventually sold it to Yahoo in early 2004. Karen Liu also worked as a consultant at McKinsey & Company from 1998-2000. Dr. Liu received her Ph.D degree in Immunology from Harvard University and Master of Medical Sciences degree from Harvard Medical School. She also received her Bachelor of Sciences degree from Cornell University and her EMBA degree from CKGSB – Chungkong Graduate School of Business in China.

Other Seats

OncoImmune

OncoImmune Management Team

4 Team Members

OncoImmune has 4 executives. OncoImmune's founder is Kun-Liang Guan. OncoImmune's current Chief Operating Officer is Martin Devenport.

Name

Work History

Title

Status

Kun-Liang Guan

Founder

Current

Ming You

Founder

Current

Pan Zheng

Founder

Current

Martin Devenport

Chief Operating Officer

Current

Name

Kun-Liang Guan

Ming You

Pan Zheng

Martin Devenport

Work History

Title

Founder

Founder

Founder

Chief Operating Officer

Status

Current

Current

Current

Current

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.